Target-based drug discovery for malaria, leishmaniasis, and trypanosomiasis.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Current Medicinal Chemistry

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/0929867003374615PMID 10828290
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of the microtubule stabilising agent taxol on leishmanial protozoan parasites in vitro.

  1999cited by this paper
• Structure-based design of submicromolar, biologically active inhibitors of trypanosomatid glyceraldehyde-3-phosphate dehydrogenase.

  1999cited by this paper
• Purification, characterization, and drug susceptibility of tubulin from Leishmania.

  1999cited by this paper
• Trypanosoma brucei: killing of bloodstream forms in vitro and in vivo by the cysteine proteinase inhibitor Z-phe-ala-CHN2.

  1999cited by this paper
• The fall and rise of sleeping sickness.

  1999cited by this paper
• Cysteine proteinase inhibitors kill cultured bloodstream forms of Trypanosoma brucei brucei.

  1999cited by this paper
• Plasmepsin II, an Acidic Hemoglobinase from thePlasmodium falciparum Food Vacuole, Is Active at Neutral pH on the Host Erythrocyte Membrane Skeleton*

  1999cited by this paper
• Pharmacological approaches to antitrypanosomal chemotherapy.

  1999cited by this paper
• Antimalarial effects in mice of orally administered peptidyl cysteine protease inhibitors.

  1999cited by this paper
• Crystal structures of adenine phosphoribosyltransferase from Leishmania donovani

  1999cited by this paper
• Malaria: new developments in treatment and prevention.

  1999cited by this paper
• Purification and characterization of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase and comparison with the human enzyme.

  1999cited by this paper
• A nucleoside transporter from Trypanosoma brucei involved in drug resistance.

  1999cited by this paper
• What Controls Glycolysis in Bloodstream Form Trypanosoma brucei?*

  1999cited by this paper
• Chloroquine Binds in the Cofactor Binding Site ofPlasmodium falciparum Lactate Dehydrogenase*

  1999cited by this paper
• Potent, low-molecular-weight non-peptide inhibitors of malarial aspartyl protease plasmepsin II.

  1999cited by this paper
• Affinity chromatography using trypanocidal arsenical drugs identifies a specific interaction between glycerol-3-phosphate dehydrogenase from Trypanosoma brucei and Cymelarsan.

  1999cited by this paper
• A general approach to the synthesis of polyamine linked-monoindolylmaleimides, a new series of trypanothione reductase inhibitors.

  1998cited by this paper
• An approach to use an unusual adenosine transporter to selectively deliver polyamine analogues to trypanosomes.

  1998cited by this paper
• A 1.4 A crystal structure for the hypoxanthine phosphoribosyltransferase of Trypanosoma cruzi.

  1998cited by this paper
• Effects of intermediates of methionine metabolism and nucleoside analogs on S-adenosylmethionine transport by Trypanosoma brucei brucei and a drug-resistant Trypanosoma brucei rhodesiense.

  1998cited by this paper
• Effects of camptothecin, a topoisomerase I inhibitor, on Plasmodium falciparum.

  1998cited by this paper
• A 2.8 A resolution structure of 6-phosphogluconate dehydrogenase from the protozoan parasite Trypanosoma brucei: comparison with the sheep enzyme accounts for differences in activity with coenzyme and substrate analogues.

  1998cited by this paper
• Trypanocidal bisbenzylisoquinoline alkaloids are inhibitors of trypanothione reductase.

  1998cited by this paper
• Structure-based design, synthesis and evaluation of conformationally constrained cysteine protease inhibitors.

  1998cited by this paper
• Crystal structure of fructose-1,6-bisphosphate aldolase from the human malaria parasite Plasmodium falciparum.

  1998cited by this paper
• Evaluation of a structure-based statine cyclic diamino amide encoded combinatorial library against plasmepsin II and cathepsin D.

  1998cited by this paper
• Cysteine Protease Inhibitors Cure an Experimental Trypanosoma cruzi Infection

  1998cited by this paper
• Structure-activity relationships in 2-aminodiphenylsulfides against trypanothione reductase from Trypanosoma cruzi.

  1998cited by this paper
• Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library.

  1998cited by this paper
• Selective tight binding inhibitors of trypanosomal glyceraldehyde-3-phosphate dehydrogenase via structure-based drug design.

  1998cited by this paper
• Emerging infectious diseases--Brazil.

  1998cited by this paper
• Diospyrin, a bisnaphthoquinone: a novel inhibitor of type I DNA topoisomerase of Leishmania donovani.

  1998cited by this paper
• Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs.

  1998cited by this paper
• Rational drug design approach for overcoming drug resistance: application to pyrimethamine resistance in malaria.

  1998cited by this paper
• A trypanosome oligopeptidase as a target for the trypanocidal agents pentamidine, diminazene and suramin

  1998cited by this paper
• Paclitaxel (Taxol)-Induced Killing ofLeishmania major in Murine Macrophages

  1998cited by this paper
• Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi.

  1998cited by this paper
• Prospects for Antiparasitic Drugs

  1998cited by this paper
• Approaching the transition state in the crystal structure of a phosphoribosyltransferase.

  1998cited by this paper
• Antimalarial Synergy of Cysteine and Aspartic Protease Inhibitors

  1998cited by this paper
• Design and synthesis of dipeptidyl alpha',beta'-epoxy ketones, potent irreversible inhibitors of the cysteine protease cruzain.

  1998cited by this paper
• Selective inhibitors of human lactate dehydrogenases and lactate dehydrogenase from the malarial parasite Plasmodium falciparum.

  1998cited by this paper
• A bisubstrate analog induces unexpected conformational changes in phosphoglycerate kinase from Trypanosoma brucei.

  1998cited by this paper
• Sugar transporters from bacteria, parasites and mammals: structure-activity relationships.

  1998cited by this paper
• Purine nucleobase transport in bloodstream forms of Trypanosoma brucei is mediated by two novel transporters.

  1997cited by this paper
• Polyamine derivatives as inhibitors of trypanothione reductase and assessment of their trypanocidal activities.

  1997cited by this paper
• Substrate and cofactor specificity and selective inhibition of lactate dehydrogenase from the malarial parasite P. falciparum.

  1997cited by this paper
• Molecular and biochemical studies on the hypoxanthine-guanine phosphoribosyltransferases of the pathogenic haemoflagellates.

  1997cited by this paper
• New spermine and spermidine derivatives as potent inhibitors of Trypanosoma cruzi trypanothione reductase.

  1997cited by this paper
• Plasmodium: drug discovery and development--an industrial perspective.

  1997cited by this paper
• Synthesis and antimalarial effects of phenothiazine inhibitors of a Plasmodium falciparum cysteine protease.

  1997cited by this paper
• New approaches to Leishmania chemotherapy: pteridine reductase 1 (PTR1) as a target and modulator of antifolate sensitivity

  1997cited by this paper
• A structure-based approach to drug discovery; crystallography and implications for the development of antiparasite drugs

  1997cited by this paper
• Glycolysis in Bloodstream Form Trypanosoma brucei Can Be Understood in Terms of the Kinetics of the Glycolytic Enzymes*

  1997cited by this paper
• Anti-plasmodial and anti-trypanosomal activity of synthetic naphtho[2,3-b]thiopen-4,9-quinones.

  1997cited by this paper
• Hemoglobin metabolism in the malaria parasite Plasmodium falciparum.

  1997cited by this paper
• Kinetoplastid glucose transporters.

  1997cited by this paper
• Rational design of selective ligands for trypanothione reductase from Trypanosoma cruzi. Structural effects on the inhibition by dibenzazepines based on imipramine.

  1997cited by this paper
• Expression and characterisation of plasmepsin I from Plasmodium falciparum.

  1997cited by this paper
• Triosephosphate isomerase from Plasmodium falciparum: the crystal structure provides insights into antimalarial drug design.

  1997cited by this paper
• Lead discovery of inhibitors of the dihydrofolate reductase domain of Plasmodium falciparum dihydrofolate reductase-thymidylate synthase.

  1997cited by this paper
• A unique transporter of S‐adenosylmethionine in African trypanosomes

  1997cited by this paper
• Biochemical and genetic tests for inhibitors of Leishmania pteridine pathways.

  1997cited by this paper
• Leishmania major: molecular modeling of cysteine proteases and prediction of new nonpeptide inhibitors.

  1997cited by this paper
• A virtual screening approach applied to the search for trypanothione reductase inhibitors.

  1997cited by this paper
• Charge is the major discriminating factor for glutathione reductase versus trypanothione reductase inhibitors.

  1996cited by this paper
• Trypanocidal analogs of myristate and myristoyllysophosphatidylcholine.

  1996cited by this paper
• Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum.

  1996cited by this paper
• Effects of cationic diamidines on polyamine content and uptake on Leishmania infantum in in vitro cultures.

  1996cited by this paper
• Kinetic analysis of plasmepsins I and II aspartic proteases of the Plasmodium falciparum digestive vacuole.

  1996cited by this paper
• Recombinant Plasmodium falciparum dihydrofolate reductase-based in vitro screen for antifolate antimalarials.

  1996cited by this paper
• The crystal structure of trypanothione reductase from the human pathogen Trypanosoma cruzi at 2.3 Å resolution

  1996cited by this paper
• Investigation of the substrate specificity of cruzipain, the major cysteine proteinase of Trypanosoma cruzi, through the use of cystatin-derived substrates and inhibitors.

  1996cited by this paper
• Hexose uptake in Trypanosoma cruzi: structure-activity relationship between substrate and transporter.

  1996cited by this paper
• Microtubule inhibitors: structure-activity analyses suggest rational models to identify potentially active compounds

  1996cited by this paper
• Proteases from Trypanosoma brucei brucei. Purification, characterisation and interactions with host regulatory molecules.

  1996cited by this paper
• 6-Phosphogluconate dehydrogenase from Trypanosoma brucei. Kinetic analysis and inhibition by trypanocidal drugs.

  1996cited by this paper
• Antimalarial effects of vinyl sulfone cysteine proteinase inhibitors

  1996cited by this paper
• Regulation of a high-affinity diamine transport system in Trypanosoma cruzi epimastigotes.

  1996cited by this paper
• The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: course and impact from 1984 to 1994.

  1996cited by this paper
• Structure-based design of parasitic protease inhibitors.

  1996cited by this paper
• Crystal structure of the Trypanosoma cruzi trypanothione reductase·mepacrine complex

  1996cited by this paper
• Inhibiting effects of spermidine derivatives on Trypanosoma cruzi trypanothione reductase.

  1996cited by this paper
• 2-Amino diphenylsulfides as inhibitors of trypanothione reductase: modification of the side chain.

  1996cited by this paper
• Characterization of native falcipain, an enzyme involved in Plasmodium falciparum hemoglobin degradation.

  1996cited by this paper
• The structure of lactate dehydrogenase from Plasmodium falciparum reveals a new target for anti-malarial design

  1996cited by this paper
• Pentamidine uptake in Leishmania donovani and Leishmania amazonensis promastigotes and axenic amastigotes.

  1996cited by this paper
• In vitro antimalarial activity of chalcones and their derivatives.

  1995cited by this paper
• Functional expression of falcipain, a Plasmodium falciparum cysteine proteinase, supports its role as a malarial hemoglobinase

  1995cited by this paper
• Antitrypanosomal activity of camptothecin analogs. Structure-activity correlations.

  1995cited by this paper
• Uptake of Diamidine Drugs by the P2 Nucleoside Transporter in Melarsen-sensitive and -resistant Trypanosoma brucei brucei(*)

  1995cited by this paper
• Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium falciparum.

  1995cited by this paper
• Kukoamine A and other hydrophobic acylpolyamines: potent and selective inhibitors of Crithidia fasciculata trypanothione reductase.

  1995cited by this paper
• Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis.

  1995cited by this paper
• Purification, characterization and localization of mitochondrial dihydroorotate dehydrogenase in Plasmodium falciparum, human malaria parasite.

  1995cited by this paper
• The crystal structure of cruzain: a therapeutic target for Chagas' disease.

  1995cited by this paper
• Cloning and expression of the adenine phosphoribosyltransferase gene from Leishmania donovani.

  1995cited by this paper
• A diamidine-resistant Trypanosoma equiperdum clone contains a P2 purine transporter with reduced substrate affinity.

  1995cited by this paper
• Toxicity of myristic acid analogs toward African trypanosomes.

  1994cited by this paper

• Uncovering therapeutic targets in Leishmania donovani through comparative network topology analysis

  2025cites this paper
• In Vitro Anthelmintic Activities of Khaya anthotheca and Faidherbia albida Extracts Used in Chad by Traditional Healers for the Treatment of Helminthiasis and In Silico Study of Phytoconstituents

  2024cites this paper
• Novel hybrids of quinoline with pyrazolylchalcones as potential antimalarial agents: Synthesis, biological evaluation, molecular docking and ADME prediction.

  2023cites this paper
• Potentials of Terpenoids as Inhibitors of Multiple Plasmodium falciparum Protein Drug Targets

  2023cites this paper
• Drug Repurposing Against Novel Therapeutic Targets in Plasmodium falciparum for Malaria: The computational perspective.

  2023cites this paper
• Guanidine based copper(II) complexes: synthesis, structural elucidation, and biological evaluation

  2022cites this paper
• Laboratory Selection of Trypanosomatid Pathogens for Drug Resistance

  2022cites this paper
• Microorganisms as a Potential Source of Molecules to Control Trypanosomatid Diseases

  2021cites this paper
• Leishmaniasis

  2021cites this paper
• The emerging paradigm of calcium homeostasis as a new therapeutic target for protozoan parasites

  2021cites this paper
• Thiazolidinone-Related Heterocyclic Compounds as Potential Antitrypanosomal Agents

  2020cites this paper
• Glyceraldehyde-3-phosphate dehydrogenase from Eimeria acervulina modulates the functions of chicken dendritic cells to boost Th1 type immune response and stimulates autologous CD4+ T cells differentiation in-vitro

  2020cites this paper
• Validation of NAD synthase inhibitors for inhibiting the cell viability of Leishmania donovani: In silico and in vitro approach

  2019cites this paper
• Molecular insights into trypanothione reductase‐inhibitor interaction: A structure‐based review

  2018cites this paper
• Secochiliolide ester derivatives: Preparation and evaluation of their antitrypanosomal and antimalarial efficacy

  2018cites this paper
• Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) Protein-Protein Interaction Inhibitor Reveals a Non-catalytic Role for GAPDH Oligomerization in Cell Death*

  2016cites this paper
• Studies on identification and in vivo function of novel drug target enzymes of Leishmania donovani using biomolecular approaches

  2016cites this paper
• GAPDH oligomerization as a switch for its functions 1 GAPDH ( glyceraldehyde-3-phosphate dehydrogenase ) Protein-Protein Interaction Inhibitor Reveals a Non-Catalytic Role for GAPDH Oligomerization in Cell Death

  2016cites this paper
• Comparative molecular field analysis and molecular docking studies on novel aryl chalcone derivatives against an important drug target cysteine protease in Plasmodium falciparum.

  2016cites this paper
• Bond-based bilinear indices for computational discovery of novel trypanosomicidal drug-like compounds through virtual screening.

  2015cites this paper
• Investigation of Novel Antimalarial Agents and Novel Target Identification Approaches

  2015cites this paper
• Cardiac and skeletal muscles show molecularly distinct responses to cancer cachexia.

  2015cites this paper
• Cardiac and Skeletal Muscles Show Molecularly Distinct Responses to Cancer 1 Cachexia 2 3

  2015cites this paper
• Role of In Silico Stereoelectronic Properties and Pharmacophores in Aid of Discovery of Novel Antimalarials, Antileishmanials, and Insect Repellents

  2015cites this paper
• Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis

  2014cites this paper
• Regulation of immunity to visceral Leishmania in a non-human primate model of infection

  2014cites this paper
• Structure prediction of gBP21 protein of L. donovani and its molecular interaction

  2014cites this paper
• Chemotherapeutic efficacy and safety of diminazene aceturate-chloroquine sulphate combination as an antileishmanial drug in balb /c mice

  2014cites this paper
• Trypanosomatidae diseases: from the current therapy to the efficacious role of trypanothione reductase in drug discovery.

  2013cites this paper
• In vitro immunobiological studies of novel 5-(5-nitrofuran-2-yl)-1, 3, 4-thiadiazoles with piperazinyl-linked benzamidine substituents against Leishmania major.

  2013cites this paper
• Role of Proteases During Intra-erythrocytic Developmental Cycle of Human Malaria Parasite Plasmodium falciparum

  2013cites this paper
• Introduction to Biochemical Pharmacology and Drug Discovery

  2013cites this paper
• Polymeric colloidal particulate systems: intelligent tools for intracellular targeting of antileishmanial cargos

  2013cites this paper
• Cell death features induced in Leishmania major by 1,3,4-thiadiazole derivatives.

  2012cites this paper
• Novel immunomodulatory function of 1,3,4-thiadiazole derivatives with leishmanicidal activity.

  2012cites this paper
• Use of cysteine-reactive small molecules in drug discovery for trypanosomal disease

  2012influential citation
• Applied Life Science Synthetic and Natural Products Against Leishmaniasis: A Review

  2012cites this paper
• Synthèse et évaluation de thiopyranones et de leur S-oxydes associés comme prodrogues de diarylidèneacétones à activité antiparasitaire

  2012cites this paper
• A fast virtual screening approach to identify structurally diverse inhibitors of trypanothione reductase.

  2011cites this paper
• Ligand-based discovery of novel trypanosomicidal drug-like compounds: in silico identification and experimental support.

  2011cites this paper
• Antiprotozoal/Antiparasitic Agents

  2010cites this paper
• Computational discovery of novel trypanosomicidal drug-like chemicals by using bond-based non-stochastic and stochastic quadratic maps and linear discriminant analysis.

  2010cites this paper
• Drug targets in Leishmania

  2010cites this paper
• Mitochondria as a promising antiparasitic target.

  2010cites this paper
• Investigation of Trypanothione Reductase as a Drug Target in Trypanosoma brucei

  2009cites this paper
• Trypanothione Reductase High-Throughput Screening Campaign Identifies Novel Classes of Inhibitors with Antiparasitic Activity

  2009cites this paper
• Current Treatment of Leishmaniasis: A Review

  2009cites this paper
• Molecular Docking of Cathepsin L Inhibitors in the Binding Site of Papain

  2008cites this paper
• Succinic semialdehyde dehydrogenase from the parasitic cattle tick Rhipicephalus microplus: gene identification, biochemical characterization and comparison with the mouse ortholog.

  2008cites this paper
• Kinetoplastids: related protozoan pathogens, different diseases.

  2008cites this paper
• Chemogenomics and parasitology: small molecules and cell-based assays to study infectious processes.

  2008cites this paper
• Structure-based Inhibitor Design for the Antimalarial Target Plasmepsin

  2008cites this paper
• Synthesis and Antimalarial Evaluation of Cyclicβ-Amino Acid-Containing Dipeptides

  2008cites this paper
• Antiprotozoal Agents (African Trypanosomiasis, Chagas Disease, and Leishmaniasis)

  2007cites this paper
• Polyamine-based analogues as biochemical probes and potential therapeutics.

  2007cites this paper
• Synthesis of marine alkaloid: 8,9-dihydrocoscinamide B and its analogues as Novel class of antileishmanial agents.

  2007cites this paper
• Synthesis of 2,3,4,7-tetrahydro-1H-azepines as privileged ligand scaffolds for the design of aspartic protease inhibitors via a ring-closing metathesis approach

  2006cites this paper
• Synthesis of 2,4,6-trisubstituted pyrimidine and triazine heterocycles as antileishmanial agents.

  2006cites this paper
• Plasmepsins as potential targets for new antimalarial therapy

  2006cites this paper
• Novel alkylpolyaminoguanidines and alkylpolyaminobiguanides with potent antitrypanosomal activity.

  2006cites this paper
• The chemotherapy of chagas' disease: an overview.

  2005cites this paper
• Irreversible inactivation of trypanothione reductase by unsaturated Mannich bases: a divinyl ketone as key intermediate.

  2005cites this paper
• Dihydropyrido[2,3-d]pyrimidines as a new class of antileishmanial agents.

  2005cites this paper
• Biogenesis of peroxisomes and glycosomes: trypanosomatid glycosome assembly is a promising new drug target.

  2004cites this paper
• Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity.

  2004cites this paper
• Screening and synthesis: high throughput technologies applied to parasitology

  2004cites this paper
• Design, synthesis and antimalarial activity of novel, quinoline-based, zinc metallo-aminopeptidase inhibitors.

  2003cites this paper
• Free energy calculations and ligand binding.

  2003cites this paper
• 8-Methoxy-naphtho[2,3-b]thiophen-4,9-quinone, a non-competitive inhibitor of trypanothione reductase.

  2003cites this paper
• The synthesis of parasitic cysteine protease and trypanothione reductase inhibitors.

  2003cites this paper
• C2-symmetric inhibitors of Plasmodium falciparum plasmepsin II: synthesis and theoretical predictions.

  2003cites this paper
• Solid-phase synthesis of a focused library of trypanothione reductase inhibitors

  2003cites this paper
• Analysis of stereoelectronic properties, mechanism of action and pharmacophore of synthetic indolo[2,1-b]quinazoline-6,12-dione derivatives in relation to antileishmanial activity using quantum chemical, cyclic voltammetry and 3-D-QSAR CATALYST procedures.

  2002cites this paper
• In vitro and in vivo anti-Trypanosoma cruzi activity of a novel nitro-derivative.

  2002cites this paper
• Coupling of a competitive and an irreversible ligand generates mixed type inhibitors of Trypanosoma cruzi trypanothione reductase.

  2002cites this paper
• Drug discovery based on functional genomics: Target selection and validation

  2002cites this paper
• Protection Against Lethal Infection Signals Via Toll-Like Receptor 2 , and Confers Induces Human Dendritic Cell Maturation , Tc 52-Released Protein Trypanosoma cruzi The Thieblemont and

  2002cites this paper
• Tubulin as an antiprotozoal drug target.

  2002cites this paper
• Using small molecules to study big questions in cellular microbiology

  2002cites this paper
• Promising therapeutic targets for antileishmanial drugs

  2002cites this paper
• The Trypanosoma cruzi Tc52-Released Protein Induces Human Dendritic Cell Maturation, Signals Via Toll-Like Receptor 2, and Confers Protection Against Lethal Infection1

  2002cites this paper
• Polyamine metabolism as chemotherapeutic target in protozoan parasites.

  2002cites this paper
• Biological characterization of a beta-galactosidase expressing clone of Trypanosoma cruzi CL strain.

  2002cites this paper
• Characterization of recombinant glutathionylspermidine synthetase/amidase from Crithidia fasciculata.

  2002cites this paper
• African trypanosomes in the 21st century: what is their future in science and in health?

  2001cites this paper
• Trypanothione as a target in the design of antitrypanosomal and antileishmanial agents.

  2001cites this paper
• Chapter 10. New therapies for parasitic infection

  2001cites this paper
• Drugs against parasitic diseases: R&D methodologies and issues, discoveries and drug development.

  2001cites this paper
• Tsetse and Trypanosomiasis Information Quarterly SECTION A – NEWS PROGRAMME AGAINST AFRICAN TRYPANOSOMIASIS

  year unknowncites this paper